Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
67.85
+5.50 (8.82%)
Apr 8, 2026, 9:30 AM EDT - Market open
Inhibrx Biosciences Market Cap
Inhibrx Biosciences has a market cap or net worth of $991.09 million as of April 8, 2026. Its market cap has increased by 377.11% in one year.
Market Cap
991.09M
Enterprise Value
893.54M
1-Year Change
377.11%
Ranking
Category
Stock Price
$67.85
Market Cap Chart
Since the IPO on May 29, 2024, Inhibrx Biosciences's market cap has increased from $198.24M to $991.09M, an increase of 399.95%. That is a compound annual growth rate of 137.83%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 7, 2026 | 910.75M | -20.73% |
| Dec 31, 2025 | 1.15B | 415.39% |
| Dec 31, 2024 | 222.93M | 12.46% |
| May 29, 2024 | 198.24M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| CytomX Therapeutics | 929.56M |
| Aktis Oncology | 924.21M |
| Vor Biopharma | 913.03M |
| GH Research | 910.59M |
| Phathom Pharmaceuticals | 910.12M |
| Janux Therapeutics | 908.22M |
| Xencor | 902.80M |
| Cullinan Therapeutics | 899.42M |